<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733079</url>
  </required_header>
  <id_info>
    <org_study_id>APHP18067</org_study_id>
    <nct_id>NCT04733079</nct_id>
  </id_info>
  <brief_title>Treat-to-target by Email During Urate-lowering Therapy in Gout</brief_title>
  <acronym>GOUTEmail</acronym>
  <official_title>Treat-to-target by Email During Urate-lowering Therapy in Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gout is secondary to urate crystal deposition after chronic elevation of serum urate level&#xD;
      (SUL). Long-term lowering SUL below 360 µmol/L allows dissolution of deposited crystals and&#xD;
      disease cure. There is currently a paradoxical observation: while urate-lowering therapy&#xD;
      (ULT) is available and efficient there is an increase of gout prevalence and severity. The&#xD;
      apparent failure of ULT in gout management is due to several causes including unadjusted&#xD;
      dosage, no SUL verification, irregular follow-up and low treatment compliance.&#xD;
&#xD;
      In contrast, a nurse-led treat-to-target (T2T) strategy with regular adaptations of ULT until&#xD;
      reaching SUL target allows gout cure in more than 90% of patients. We hypothesize that an&#xD;
      electronic messaging-led T2T strategy will allow obtaining similar results.&#xD;
&#xD;
      The aim of this study is to demonstrate that email-led T2T strategy during ULT is superior to&#xD;
      usual care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 204 gouty patients without ULT or with ineffective ULT. This is a&#xD;
      multicenter and randomized study (e-mail follow-up vs usual follow-up groups).&#xD;
&#xD;
      This study will include the following visits:&#xD;
&#xD;
        -  Selection/inclusion visit (V0):&#xD;
&#xD;
             -  If available biological data (leucocyte count, hemoglobin level, creatininemia and&#xD;
                estimated glomerular filtration rate (eGFR), SUL) were assessed during the last&#xD;
                month, , included patient will be randomized at the end of the consultation to&#xD;
                follow either an email-led T2T strategy or usual ULT care.&#xD;
&#xD;
             -  In the absence of biological results, the patient will be reviewed within the month&#xD;
                with blood analysis and then randomized.&#xD;
&#xD;
        -  Follow-up visits: consultations will be carried out according to the usual care of the&#xD;
           referring physician.&#xD;
&#xD;
        -  Visit M12 end of research: clinical evaluation of gout, demographic characteristics,&#xD;
           medication, type and dose of ULT, blood analysis (serum creatinine level, eGFR, SUL).&#xD;
&#xD;
      The study ends after the M12 consultation. The total duration of participation in the study&#xD;
      is 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with target SUL (&lt;360 μmol /L or &lt;300 μmol /L in tophaceous gout)</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average dose of ULT (allopurinol and febuxostat)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Gout</condition>
  <condition>Inflammatory Rheumatism</condition>
  <condition>Hyperuricemia</condition>
  <condition>Posology Adjustment</condition>
  <arm_group>
    <arm_group_label>E-mail follow-up group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Email-led treat-to-target strategy with regular adaptation of ULT via electronic messaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual follow-up group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adaptation and follow-up of ULT according to referring physician's habits</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cleanweb electronic messaging ePro</intervention_name>
    <description>Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached</description>
    <arm_group_label>E-mail follow-up group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual follow-up</intervention_name>
    <description>Adaptation and follow-up of ULT according to referring physician's habits</description>
    <arm_group_label>Usual follow-up group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged over 18 years old&#xD;
&#xD;
          -  Gout confirmed by identification of urate crystals by joint fluid or tophus analysis&#xD;
             or by ultrasound of the affected joint or&#xD;
&#xD;
          -  Gout according to Nijmegen criteria (presence of a score ≥ 8/13) depending on the&#xD;
             following items:&#xD;
&#xD;
        Man (2 pts) Previous crisis (2 pts) Involvement of first metatarsophalangeal joint (MTP1)&#xD;
        (2.5 pts) Maximum pain within 24 hours (0.5pt) Redness (1 pt) HTA or cardiovascular disease&#xD;
        (1.5 pts) SUL &gt; 360 μmol/l during the crisis (3.5 pts)&#xD;
&#xD;
          -  Patients without ULT or with an ineffective ULT defined by an SUL &gt; 360 μmol/l in&#xD;
             intercritical pahse&#xD;
&#xD;
          -  Patients who routinely use e-mail&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participating in another trial including the administration of a drug&#xD;
&#xD;
          -  Patients treated with azathioprine&#xD;
&#xD;
          -  Patients intolerant to hypouricemic treatments&#xD;
&#xD;
          -  Unable to use the internet&#xD;
&#xD;
          -  Difficulty understanding French&#xD;
&#xD;
          -  Illiteracy&#xD;
&#xD;
          -  Pregnant womenor breastfeeding mothers (see PHC article L.1121-5)&#xD;
&#xD;
          -  Persons deprived of liberty by judicial or administrative decision, persons receiving&#xD;
             psychiatric care under Sections L. 3212-1 and L. 3213-1 and persons admitted to a&#xD;
             health or social institution for purposes other than research (see CSP Article&#xD;
             L.1121-6)&#xD;
&#xD;
          -  Major persons subject to a measure of legal protection or unseeding to express consent&#xD;
             (see PHC Article L.1121-8)&#xD;
&#xD;
          -  Persons not affiliated to a social security plan or beneficiaries of such a plan (see&#xD;
             PHC Article L.1121-8-1)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Korng EA, PH-PU</last_name>
    <phone>1 49 95 88 25</phone>
    <phone_ext>+33</phone_ext>
    <email>hang-korng.ea@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital LARIBOISIERE - Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treat-to-target</keyword>
  <keyword>Gout</keyword>
  <keyword>Tophus</keyword>
  <keyword>Urate crystals</keyword>
  <keyword>Urate-lowering therapy</keyword>
  <keyword>Febuxostat</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Therapeutic strategy</keyword>
  <keyword>Electronic messaging</keyword>
  <keyword>Therapeutic compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Gout</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

